Anti-inflammatory peptides derived from C-reactive protein

Details Anti-inflammatory peptides derived from C-reactive protein Anti-inflammatory peptides derived from C-reactive protein

2000-03-28

2003-03-04

Nashed, Nashaat T. (Department: 1652)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

15 to 23 amino acid residues in defined sequence

C435S212000, C435S218000, C435S219000, C514S002600, C514S015800, C530S300000, C530S328000

Reexamination Certificate

active

06528618

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to synthetic peptides derived from the primary sequence of the acute phase reactant C-reactive protein (CRP) (SEQ ID NO:1), more particularly to a peptide corresponding to positions 62-71 of CRP and derivatives thereof, which peptides inhibit in vitro the enzymatic activities of human leukocyte elastase (hLE) and/or human leukocyte cathepsin G (hCG), two potent serine proteases associated with tissue damage occurring in the course of several chronic inflammatory conditions. The invention further relates to anti-inflammatory pharmaceutical compositions comprising said CRP-derived peptides.
Abbreviations
The following abbreviations will be used throughout the specification:
CRP, C-reactive protein; hLE, human leukocyte elastase; hCG, human leukocyte cathepsin G; MeOSuc-AAPV-NA, methoxysuccinyl-Ala-Ala-Pro-Val-nitroanilide (SEQ ID NO:2), Suc-AAPF-NA, succinyl-Ala-Ala-Pro-Phe-nitroanilide (SEQ ID NO:3).
BACKGROUND OF THE INVENTION
C-reactive protein (CRP) is a plasma protein classified as a major acute phase reactant due to its dramatic accumulation in the blood stream during the inflammatory response. Within a relatively short period (24-48 hr) following tissue injury or certain traumatic events, the CRP blood concentration may rise 1000-fold over the normal level to as high as 1 mg/ml (Ballue and Kushner, 1992).
CRP consists of five identical sub-units that contain each 206 amino acids bridged by a single disulfide bond and that aggregate non-covalently into a cyclic pentamer termed pentraxin. The precise biochemical function of CRP as a whole entity is still obscure. CRP was shown to bind to specific receptors on human neutrophils (K
d
~5×10
−8
M), monocytes (K
d
~10
−7
M), and other inflammatory-related cells in vitro (Ballue and Kushner, 1992),
In the laboratories of the present inventors and their collaborators it was found that following binding to neutrophils, CRP is subsequently degraded by a membrane-associated neutral serine protease, which has been characterized (Shephard et al., 1992), and by lysosomal-derived enzymes to yield various low molecular weight peptides. Several of these peptides were identified, synthesized, and shown to be potent anti-inflammatory agents inhibiting neutrophil phagocytosis, degranulation, and superoxide ion (O
2
) generation (Shephard et al., 1990; Yavin et al., 1995). Superoxide ion is the parent compound of several destructive mediators that are believed to play a central role in inflammation-associated tissue injury (Ballue and Kushner, 1992).
The most prominent of the peptides disclosed by Shephard et al., 1990, and Yavin et al., 1995, were derived from within the primary sequence of CRP (SEQ ID NO:1) as follows: Asp
70
-Ile-Gly-Tyr-Ser
74
, Lys
201
-Pro-Gln-Leu-Trp-Pro
206
, Leu
83
-Phe-Glu-Val-Pro-Glu-Val-Thr
90
, Val-
77
-Gly-Gly-Ser-Glu-Ile
82
(Shephard et al., 1990) and Asn
160
-Met-Trp-Asp-Phe-Val
165
, Gln
203
-Leu-Trp-Pro
206
, Ser
18
-Tyr-Val-Ser-Leu-Lys
23
(Yavin et al., 1995). These peptides were shown by the authors to inhibit various neutrophilic functions, indicating that they may be capable of regulating superoxide ion production by neutrophils in vivo during the acute phase response as part of a complex protective mechanism. However, as disclosed in the PCT Publication No. WO 97/28182 of the same applicants, several of these peptides lack hLE inhibitory capability.
Human leukocyte elastase (hLE) and human leukocyte cathepsin G (hCG) are the two major potent neutral serine proteases found in the azurophilic granules of neutrophils which are involved in the intracellular digestion of proteins and play an important role in phagocytosis and host defense against invading organisms. In the extracellular environment, hLE is capable of degrading various connective tissue proteins including highly cross-linked elastin whereas hCG is very effective in degrading proteoglycans and collagens and has been shown to augment the elastolytic capability of hLE (Groutas, 1987).
The release of enzymes into the extracellular medium by activated neutrophils is normally controlled by several potent inhibitors. The most specific natural inhibitors, &agr;
1
-protease inhibitor (&agr;
1
-PI) and &agr;-antichymotrypsin (ACT), are directed against hLE and hCG, respectively (Groutas, 1987). Imbalances in the levels of tissue proteases such as hLE and hCG, and their inhibitors, allow excess hLE and hCG to attack connective tissue, and are implicated in the severe and permanent tissue damage associated with pulmonary emphysema (Groutas, 1987), rheumatoid arthritis (Gallin et al., 1988), cystic fibrosis (Jackson et al., 1984) and several other inflammatory conditions. Major research efforts have been dedicated to develop potent inhibitors of hLE and hCG based on a wide variety of low molecular weight organic compounds (Edwards and Bernstein, 1994) such as 3,3-dialkylazetidin-2-ones, proposed as orally active &bgr;-lactam inhibitors of hLE (Finke et al., 1995).
CRP as a whole protein was reported to have no inhibitory effect on hLE (Vachino et al., 1988). In contrast, a specific region within the primary sequence of CRP containing the core peptide Val
89
-Thr-Val-Ala-Pro-Val-His-Ile
96
of SEQ ID NO:1 was shown to inhibit in vitro the enzymatic activities of hLE and hCG to a larger extent than peptides of similar chain lengths corresponding to the active sites of their natural inhibitors (PCT Publication No. WO 97/28182; Yavin et al., 1996). Novel biologically active CRP-derived peptides, i.e. peptides capable of inhibiting in vitro the enzymatic activity of hLE and/or of hCG, previously concealed within the inner hydrophobic disulfide loop which spans CRP36-97 in each subunit (see FIG.
1
), have been found in accordance with the present invention to significantly inhibit the enzymatic activities of hLE and hCG enzymes.
SUMMARY OF THE INVENTION
The present invention relates to a synthetic CRP-derived peptide capable of inhibiting in vitro the enzymatic activity of human leukocyte elastase (hLE) and/or of human cathepsin G (hCG), said peptide being selected from:
(i) a core peptide corresponding to positions 62-71 of the sequence of human C-reactive protein (CRP) of the formula:
Glu
62
-Ile-Leu-Ile-Phe-Trp-Ser-Lys-Asp-Ile
71
or peptides resulting from modification thereof characterized by:
(ii) substitution of Glu
62
by Asp or by a non-amino acid negatively charged residue derived from succinic, glutaric or adipic acids;
(iii) substitution of each of the residues Ile
63
, Leu
64
, Ile
65
, Phe
66
or Trp
67
by a natural or non-natural hydrophobic amino acid residue;
(iv) deletion of 1 or 2 amino acid residues selected from Ile
63
, Leu
64
, Ile
65
, Phe
66
and Trp
67
;
(v) substitution of 1-3 amino acid residues selected from Ile
63
, Leu
64
, Ile
65
, Phe
66
and Trp
67
by a single non-natural amino acid residue derived from 6-aminocaproic acid;
(vi) substitution of 2-4 amino acid residues selected from Ile
63
, Leu
64
, Ile
65
, Phe
66
and Trp
67
by a single non-natural amino acid residue derived from 8-aminocaproic acid, 10-aminodecanoic acid or 12-aminolauric acid;
(vii) substitution of 3-5 amino acid residues selected from Ile
63
, Leu
64
, Ile
65
, Phe
66
and Trp
67
by a stretch of identical hydrophobic amino acid residues or by a single non-natural amino acid residue derived from 10-aminodecanoic acid or 12-aminolauric acid;
(viii) substitution of Ser
68
by a natural or non-natural amino acid residue selected from Thr, Cys, Ala and homoserine;
(ix) substitution of Lys
69
by a natural or non-natural positively charged or hydrophobic amino acid residue;
(x) substitution of Asp
70
by a negatively charged or a polar amino acid residue selected from Glu, Asn or Gln;
(xi) substitution of Ile
71
by a natural or non-natural hydrophobic amino acid residue;
(xii) elongation of a peptide (i) to (xi) by 1-5 non-charged amino acid residues at the N-terminus and/or at the C-terminus;
(xiii) substitution of any amino acid residue in a peptide (i) to (xii) by the correspondi

Affiliated with

Also associated with

Rating

Anti-inflammatory peptides derived from C-reactive protein does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-inflammatory peptides derived from C-reactive protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-inflammatory peptides derived from C-reactive protein will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3046561